<DOC>
	<DOCNO>NCT01095016</DOCNO>
	<brief_summary>This open-label , randomize , cross-over , active-controlled study evaluate efficacy safety effect use Meptin® Swinghaler Berotec N® Metered Aerosol stable asthma patient</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Meptin® Swinghaler Berotec N® Metered Aerosol Mild Moderate Stable Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fenoterol</mesh_term>
	<criteria>Male female outpatient age ≥18 year old uncontrolled partly control asthma ; Stability assess past 14 day patient remain severity class 2006 GINA guideline ( uncontrolled , partly control ) acute exacerbation investigator judgment ; Pulmonary function test : Improvement ≥12 % reversibility FEV1 FVC follow administration inhale β2agonist study ; Positive result Brochoprovocation test ; Hypersensitivity β2agonist lactose ; Hospitalization due asthma previous 3 month ; Respiratory tract infection require treatment antibiotic previous 4 week ; Oral systemic corticosteroid previous 4 week ; Inadequately control hyperthyroidism ; Subjects clinically significant disorder cardiovascular , neurologic , hematologic , gastrointestinal , cerebrovascular , immunologic system respiratory disease asthma ( e.g . COPD ) , disorder may interfere wth study evaluation affect subject safety ; Patients receive investigational drug within 30 day prior admission study ; Patients significant alcohol , drug medication abuse judged investigator ; Females pregnant breastfeeding ; ( exception : Females childbearing age might include , opinion investigator , use adequate contraceptive precaution ) ; Subjects heavy smoker ( 10 pack year ) smoking within previous 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>